[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2019",
          "fs": "Sep 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7eUAA"
          },
          "Id": "a0P2P0000078q7eUAA",
          "Event_Date__c": "2019-09-25",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "Sep 2019",
          "Status_History__c": "a132P000000BiVSQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "<p>2020-02: Received Clinician Application</p>",
          "fs": "<p>2020-02: Received Clinician Application</p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2020",
          "fs": "Feb 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Received Additional Information",
          "fs": "Received Additional Information",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7fUAA"
          },
          "Id": "a0P2P0000078q7fUAA",
          "Event_Date__c": "2020-02-29",
          "Event_Description__c": "Received Additional Information",
          "Stage__c": "Application Received",
          "Summary__c": "<p>2020-02: Received Clinician Application</p>",
          "Formatted_Date__c": "Feb 2020",
          "Status_History__c": "a132P000000Br9lQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "<p>2020-04: Received Clinician Application</p>",
          "fs": "<p>2020-04: Received Clinician Application</p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2020",
          "fs": "Apr 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Received Additional Information",
          "fs": "Received Additional Information",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7gUAA"
          },
          "Id": "a0P2P0000078q7gUAA",
          "Event_Date__c": "2020-04-30",
          "Event_Description__c": "Received Additional Information",
          "Stage__c": "Application Received",
          "Summary__c": "<p>2020-04: Received Clinician Application</p>",
          "Formatted_Date__c": "Apr 2020",
          "Status_History__c": "a132P000000Br9mQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "<p>2020-05: Received Supplier Application</p>",
          "fs": "<p>2020-05: Received Supplier Application</p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2020",
          "fs": "May 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Received Additional Information",
          "fs": "Received Additional Information",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7hUAA"
          },
          "Id": "a0P2P0000078q7hUAA",
          "Event_Date__c": "2020-05-14",
          "Event_Description__c": "Received Additional Information",
          "Stage__c": "Application Received",
          "Summary__c": "<p>2020-05: Received Supplier Application</p>",
          "Formatted_Date__c": "May 2020",
          "Status_History__c": "a132P000000Br9qQAC"
        },
        "change": null
      }
    ],
    "dateString": "Sep 2019",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2020",
          "fs": "Jun 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7iUAA"
          },
          "Id": "a0P2P0000078q7iUAA",
          "Event_Date__c": "2020-06-11",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Jun 2020",
          "Status_History__c": "a132P000000Br9bQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2020",
          "fs": "Jun 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 3 July 2020",
          "fs": "Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 3 July 2020",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7jUAA"
          },
          "Id": "a0P2P0000078q7jUAA",
          "Event_Date__c": "2020-06-18",
          "Event_Description__c": "Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 3 July 2020",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Jun 2020",
          "Status_History__c": "a132P000000BsYaQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that gemtuzumab ozogamicin (one dose only, with intensive chemotherapy) be funded for the treatment of <i>de novo</i> acute myeloid leukaemia with a high priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Initial application \u2014 only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has not received prior chemotherapy for this condition; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has de novo CD33-positive acute myeloid leukaemia; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient does not have acute promyelocytic leukaemia; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">4</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC); and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">5</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient is being treated with curative intent; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">6</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient\u2019s disease risk has been assessed by cytogenetic testing to be good or intermediate; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient must be considered eligible for standard intensive remission induction chemotherapy with daunorubicin and cytarabine; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">8</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Gemtuzumab ozogamicin to be funded for one dose only.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Notes: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (e.g. myelodysplasia or myeloproliferative disorder).</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>In making this recommendation, the Subcommittee noted that the supplier of gemtuzumab ozogamicin had requested funding for five doses. However, the Subcommittee considered that the incremental benefit of five doses, compared with a single dose, was not sufficient to warrant the additional four doses. The Subcommittee considered that there was likely a small additional benefit in relapse rate and survival from five doses compared with that provided by one dose of gemtuzumab ozogamicin, and that the potential for treatment-related toxicity may also preclude subsequent transplant.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(62, 62, 60);\">The Subcommittee also considered that, if PHARMAC was only able to fund one of these medicines (i.e gemtuzumab ozogamicin or midostaurin) for the treatment of patients with favourable, intermediate or undetermined risk AML, the greater clinical benefit could be obtained through first funding gemtuzumab ozogamicin, as this would result in benefits for a wider population rather than a defined subset of the population.</span></p><p style=\"text-align: justify;\"><br></p>",
          "fs": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that gemtuzumab ozogamicin (one dose only, with intensive chemotherapy) be funded for the treatment of <i>de novo</i> acute myeloid leukaemia with a high priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Initial application \u2014 only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has not received prior chemotherapy for this condition; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has de novo CD33-positive acute myeloid leukaemia; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient does not have acute promyelocytic leukaemia; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">4</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC); and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">5</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient is being treated with curative intent; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">6</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient\u2019s disease risk has been assessed by cytogenetic testing to be good or intermediate; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient must be considered eligible for standard intensive remission induction chemotherapy with daunorubicin and cytarabine; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">8</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Gemtuzumab ozogamicin to be funded for one dose only.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Notes: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (e.g. myelodysplasia or myeloproliferative disorder).</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>In making this recommendation, the Subcommittee noted that the supplier of gemtuzumab ozogamicin had requested funding for five doses. However, the Subcommittee considered that the incremental benefit of five doses, compared with a single dose, was not sufficient to warrant the additional four doses. The Subcommittee considered that there was likely a small additional benefit in relapse rate and survival from five doses compared with that provided by one dose of gemtuzumab ozogamicin, and that the potential for treatment-related toxicity may also preclude subsequent transplant.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(62, 62, 60);\">The Subcommittee also considered that, if PHARMAC was only able to fund one of these medicines (i.e gemtuzumab ozogamicin or midostaurin) for the treatment of patients with favourable, intermediate or undetermined risk AML, the greater clinical benefit could be obtained through first funding gemtuzumab ozogamicin, as this would result in benefits for a wider population rather than a defined subset of the population.</span></p><p style=\"text-align: justify;\"><br></p>",
          "change": null
        },
        "Published_Discussion": {
          "s": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0</span>The Subcommittee noted that acute myeloid leukaemia (AML) is a haematopoietic neoplasm involving clonal proliferation of myeloid precursor cells, leading to increased production of immature malignant cells and a reduction in mature myeloid cells. The Subcommittee noted that AML is a highly symptomatic, rapidly progressing disease that results in a variety of systemic consequences (e.g. anaemia, bleeding, and an increased risk of infection) due to bone marrow failure or the presence of AML blasts in the bone marrow, peripheral blood or other organs, with poor overall survival. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that patients with AML spend a substantial amount of time in hospital for disease management, treatment administration, supportive care and investigations; this inpatient duration may be weeks or months for patients who receive intensive chemotherapy. The Subcommittee noted evidence where the caregivers of patients with AML, in addition to patients themselves, experienced post-traumatic stress (<a href=\"https://pubmed.ncbi.nlm.nih.gov/24673368/\" target=\"_blank\">Leunis et al. Eur J Haematol. 2014;93:198-206</a>, <a href=\"https://pubmed.ncbi.nlm.nih.gov/26014209/\" target=\"_blank\">Jia et al. Psychooncology. 2015;24:1754-60</a>). Members considered the impact on family and wh\u0101nau is due to the need to support the patient with AML through this long and difficult illness. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that AML is the most common acute leukaemia diagnosed in New Zealand adults, with incidence estimated to be 6-9 per 100,000 in the population in 2016 (<a href=\"https://pubmed.ncbi.nlm.nih.gov/29860482/\" target=\"_blank\">Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2018;4:1553-68</a>). However, Members estimated that if AML secondary to prior haematological malignancy or previous treatment of malignant disease is excluded, the incidence of <i>de novo</i> AML in New Zealand is lower, closer to 3.5 per 100,000. The Subcommittee noted that AML incidence increases with age and that the median age at diagnosis is between 65 to 70 years. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that M\u0101ori have an increased risk of AML relative to New Zealand Caucasians (<a href=\"https://pubmed.ncbi.nlm.nih.gov/15929115/\" target=\"_blank\">Tracey et al. Am J Hematol. 2005;79:114-8</a>) and that M\u0101ori have reduced chances of finding suitable stem cell donors from international registries, leading to disproportionately less stem cell transplantation as part of therapy for AML.<span style=\"background-color: yellow; font-size: 7pt;\"> </span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that standard of care diagnostic investigation of patients with AML includes bone marrow sampling, molecular testing and immunophenotyping via flow cytometry; the latter of which would detect the cell surface antigen CD33 that is present for approximately 85\u201390% of patients with AML. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the health need and probability of survival for patients with AML is predominantly influenced by age and cytogenetic risk profile which can be categorised as favourable or intermediate (combined, these account for about 70% of <i>de novo</i> AML) or as adverse (~30% of cases). The Subcommittee noted that molecular testing identifies a range of genetic mutations in AML which occur in different patterns and combinations, contributing to a patient\u2019s cytogenetic risk: </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.6.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the FLT3 (FMS-like tyrosine kinase 3) mutation occurs in about one-third of patients with AML. The Subcommittee considered that patients with FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) experience more frequent and earlier disease relapse leading to poor survival.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.6.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that patients with acute promyelocytic leukaemia (APL) have a particular, mutation, that is associated with good outcomes from current treatment, therefore patients with APL were considered out of scope for the current funding applications. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.7.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that cytogenetic testing is routinely available across New Zealand and that results are generally available within 48 to 72 hours. The Subcommittee considered it important for cytogenetic results to be available before treatment commences to ensure therapy is optimal with regard to the patient\u2019s cytogenetics, however, unavoidable delays (e.g. due to public holidays) are known to lead to additional supportive care requirements while results are pending. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.8.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that approximately half to three-quarters of younger patients (generally defined as those aged less than 60 years) with AML are suitable for intensive induction and consolidation chemotherapy with anthracycline (e.g. daunorubicin) and cytarabine, both which are currently funded without restriction and remain the backbone of intensive treatment for AML. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.9.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that many New Zealand patients with AML have participated in UK-based clinical trials, most recently the AML-19 trial; a randomised, factorial design, open-label, phase III trial comparing several different treatment strategies (including gemtuzumab ozogamicin and midostaurin) in adults with <i>de novo</i> AML who are suitable for intensive chemotherapy. Members considered that early data from the AML-19 trial suggests an improvement in long-term survival in younger patients.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.10.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that azacitidine is not used to treat patients with AML who are deemed suitable for treatment with intensive chemotherapy. The Subcommittee considered that azacitidine is generally used in patients of older age, those who are frail, have low AML blast cell counts and have adverse cytogenetics. As a result, the Subcommittee considered that any widening of access to azacitidine for patients with AML would not affect the treatment paradigm for patients with AML who are suitable candidates for intensive chemotherapy.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.11.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that disease relapse, which is accompanied by a return of symptoms due to blast cell re-emergence, is of high unmet clinical need for patients with AML as there are limited subsequent treatment options and often very shortened survival post-relapse. The Subcommittee noted that younger patients with AML who receive intensive treatment have 5 year-survival rates of about 50% at 5 years and this rate has improved over past decades, predominantly driven by improved understanding of the disease, therapeutic approaches and molecular testing in clinical trials; however, patients over 60 have a lower rate of survival (about 25% at 5 years) and this has not improved substantially over past decades.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.12.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>Members noted that patients with AML with intermediate or adverse disease risk that is in remission after intensive chemotherapy treatment may be fit enough to undergo allogenic stem cell transplant, leading to better outcomes for such patients; however, older patients (e.g. patients over 60 years of age) may not be suitable candidates for transplant and therefore are unable to receive this additional benefit.</p><p style=\"text-align: justify;\"><br></p><h2>Gemtuzumab ozogamicin</h2><p style=\"text-align: justify;\"><span style=\"color: black;\">1.13.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that in February <a href=\"https://connect.pharmac.govt.nz/apptracker/s/application-public/a0R2P000000MazW\" target=\"_blank\">2015</a>, PHARMAC received a clinician application to fund gemtuzumab ozogamicin in New Zealand for favourable and intermediate-risk AML within the context of the UK Medical Research Council (UK MRC) cooperative group trial, AML-19. The Subcommittee noted that the AML-19 clinical trial was discussed by CaTSoP in <a href=\"https://www.pharmac.govt.nz/assets/ptac-cancer-treatments-subcommittee-minutes-2015-03.pdf\" target=\"_blank\">March 2015</a> and that the clinician application was reviewed by <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf\" target=\"_blank\" style=\"color: windowtext;\">PTAC in </a><a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf\" target=\"_blank\">May 2015</a>, who noted gemtuzumab ozogamicin was not commercially available and recommended it be declined due to insufficient evidence to support funding it on the Pharmaceutical Schedule; subsequently, an exemption to the Hospital Medicines List was granted, enabling gemtuzumab ozogamicin use within the AML-19 clinical trial, for a maximum of three years. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.14.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that gemtuzumab ozogamicin is a monoclonal antibody to CD33 linked to a cytotoxic agent that selectively targets CD33-positive AML blast cells and induces cell death while selectively minimising the impact on cells and tissues that do not express CD33. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.15.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that a regulatory application for gemtuzumab ozogamicin was submitted to Medsafe in May 2020, and at this review this application was considered to meet PHARMAC\u2019s criteria for consideration under the parallel assessment pathway which provides for consideration of cancer medicines at the same time as they are assessed by Medsafe. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.16.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that gemtuzumab ozogamicin is available as 5 mg powder concentrate for infusion in a single-use vial and the applicants state it would be administered at a dose of 3 mg per m<sup>2</sup>, capped at 5 mg per dose, in combination with standard intensive anthracycline and cytarabine chemotherapy. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.17.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the supplier requested funding for three doses during induction therapy and up to two doses for consolidation therapy (total of five doses), however, the clinician applicants\u2019 requested that gemtuzumab ozogamicin be funded for one or two doses for induction therapy only. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.18.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the supplier additionally defined the patient group being considered for treatment with gemtuzumab ozogamicin as those who have CD-33 positive disease, whereas the clinician applicants defined the target patient group as those with good, intermediate or unknown cytogenetic risk treated with curative intent.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.19.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the key clinical trial evidence for gemtuzumab ozogamicin comes from the randomised (1:1), phase III, open-label ALFA 0701 trial, which investigated standard induction (daunorubicin 60 mg/m<sup>2</sup> and cytarabine 200 mg/m<sup>2</sup>), consolidation therapy (daunorubicin 60 mg/m<sup>2</sup> cytarabine 1 g/m<sup>2</sup>) with or without gemtuzumab ozogamicin 3 mg per m<sup>2 </sup>on days 1, 4, and 7 of induction and day 1 of consolidation courses (total of 5 doses) in 280 patients aged 55 to 70 years with previously untreated de novo acute AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/22482940/\" target=\"_blank\">Castaigne et al. Lancet. 2012;379:1508-16</a>). </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.20.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the primary outcome of ALFA 0701 was event free .survival (EFS, defined as time from randomisation to relapse, death [any cause], or failure to achieve complete remission [CR] or complete remission with incomplete haematological recovery [CRp]) and that following a relapse event, patients could undergo salvage treatment. The Committee noted that 177 of 280 patients tolerated the treatment well enough to receive the entire regimen. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.21.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the ALFA 0701 trial results report an improvement in EFS (HR 0.58, 95% CI: 0.43-0.78; P=0.0003) and a lesser improvement in overall survival (OS) (HR for death 0.69, 95% CI: 0.49-0.98; P=0.0368). The Subcommittee considered that salvage treatment of patients post-relapse could have resulted in some of the reported OS benefit. The Subcommittee noted that the rates of death due to major toxicity were similar between the treatment groups. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.22.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that persistent grade 4 thrombocytopenia was reported in in 22 patients (16%) receiving gemtuzumab ozogamicin in the ALFA 0701 trial compared with 4 patients (3%) in the control group (P&lt;0.0001), longer treatment-induced neutropenia was reported in patients receiving gemtuzumab ozogamicin, and there were generally increased rates of grade 3 and 4 adverse events in patients receiving gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.23.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the ALFA 0701 trial final OS results, which reported a modest improvement in OS (although not statistically significant) with median OS 27.5 months (95% CI: 21.4-45.6) with gemtuzumab ozogamicin compared with 21.8 months (95% CI: 15.5-27.4) in the control group (HR 0.81, 95% CI: 0.60-1.09; 2-sided <i>P</i>=0.16) (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\">Lambert et al. Haematologica. 2019;104:113-9</a>). The Subcommittee noted that OS analysis in patient subsets indicated that younger patients and patients with favourable and intermediate cytogenetic risk receive a survival benefit (HR: 0.46, 95% CI: 0.31-0.68; <i>P</i>&lt;0.0001); however, the data indicated that patients with unfavourable cytogenetics (irrespective of mutation e.g. FLT3, NPM1 or other type) did not benefit from the addition of gemtuzumab ozogamicin (HR: 1.11, 95% CI: 0.63-1.95;P=0.72). Members noted that the trial population included more patients with intermediate cytogenetic risk than favourable cytogenetic risk (<a href=\"https://www.thelancet.com/action/showPdf?pii=S0140-6736%2812%2960485-1\" target=\"_blank\">Castaigne et al. Lancet. 2012;379:1508-16</a>). Members considered despite the limited trial data for patients with favourable cytogenetic risk it was likely that they also benefitted from treatment with gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.24.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the results of a meta-analysis of five randomised controlled trials, in which gemtuzumab ozogamicin was used at a dose of 3 mg per m<sup>2</sup> (single or multiple doses) or at 6 mg per m<sup>2</sup> as part of intensive induction therapy in a total of 3,325 adult patients with AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\">Hills et al. Lancet Oncol. 2014;15:986-96</a>). The Subcommittee noted that this meta-analysis included the open-label, randomised AML-15 trial in patients with AML (excluding APL) who were mostly less than 60 years of age (<a href=\"https://pubmed.ncbi.nlm.nih.gov/21172891/\" target=\"_blank\">Burnett et al. J Clin Oncol. 2011; 29:369-77</a>). </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.25.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the meta-analysis by Hills et al. reported that the rate of remission was unchanged, the risk of relapse was reduced (odds ratio [OR]: 0.81, 95% CI: 0.73 \u2013 0.90, <i>P</i>=0.0001) and OS at five years was increased (OR: 0.90, 95% CI: 0.82 \u2013 0.98, <i>P</i>=0.01) with gemtuzumab ozogamicin in intensively treated patients. The Subcommittee noted that after treatment with gemtuzumab ozogamicin, 20.7% (OR: 0.47) more patients with favourable cytogenetic risk and 5.7% (OR: 0.84) more patients with intermediate risk respectively remained alive after 6 years than those who did not receive gemtuzumab ozogamicin, however, those with adverse risk cytogenetics did not benefit from gemtuzumab ozogamicin. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.26.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee also noted the applicant-submitted data for gemtuzumab ozogamicin from the AAML0531 trial in patients aged 0 to 29 years with newly diagnosed AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25092781\" target=\"_blank\">Gamis et al. J Clin Oncol. 2014;32:3021-32</a>).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.27.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that approximately 88 patients with AML would be fit for intensive chemotherapy each year in New Zealand, of which approximately three-quarters (66 patients) would have favourable, intermediate or undetermined cytogenetics and would therefore be potentially eligible for gemtuzumab ozogamicin. The Subcommittee considered this estimate was sufficiently close to that of the applicants (45 patients per year).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.28.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that gemtuzumab ozogamicin would provide a treatment benefit for the group of patients with AML with favourable, intermediate or undetermined cytogenetic risk and therefore the funded benefit would reach many people with AML. The Subcommittee considered that the use of gemtuzumab ozogamicin, if funded, would not change usage of other funded medicines used to treat AML, however there may be additional platelet transfusion requirements as more patients would achieve complete remission with incomplete platelet recovery after treatment with gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.29.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that the Special Authority criteria for gemtuzumab ozogamicin should include favourable and intermediate, but not unknown, cytogenetic risk; treatment with gemtuzumab ozogamicin should be commenced after cytogenetic testing results are made available.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.30.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that, based on the mature published evidence and unpublished emerging evidence (i.e. AML 19 trial data) for gemtuzumab ozogamicin at this time, a single dose of gemtuzumab ozogamicin would likely provide sufficient benefit in terms of relapse rate and survival compared with two or five doses for patients with favourable, intermediate or undetermined risk AML, noting the risk of liver toxicity or thrombocytopenia that may develop as a result of additional doses during intensive treatment, and which may preclude subsequent transplant, as well as the incremental cost of additional doses. The Subcommittee considered that it was reasonable to specify a maximum of one dose of gemtuzumab ozogamicin in the Special Authority criteria based on this assessment.\u00a0</p><p style=\"text-align: justify;\"><br></p>",
          "fs": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0</span>The Subcommittee noted that acute myeloid leukaemia (AML) is a haematopoietic neoplasm involving clonal proliferation of myeloid precursor cells, leading to increased production of immature malignant cells and a reduction in mature myeloid cells. The Subcommittee noted that AML is a highly symptomatic, rapidly progressing disease that results in a variety of systemic consequences (e.g. anaemia, bleeding, and an increased risk of infection) due to bone marrow failure or the presence of AML blasts in the bone marrow, peripheral blood or other organs, with poor overall survival. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that patients with AML spend a substantial amount of time in hospital for disease management, treatment administration, supportive care and investigations; this inpatient duration may be weeks or months for patients who receive intensive chemotherapy. The Subcommittee noted evidence where the caregivers of patients with AML, in addition to patients themselves, experienced post-traumatic stress (<a href=\"https://pubmed.ncbi.nlm.nih.gov/24673368/\" target=\"_blank\">Leunis et al. Eur J Haematol. 2014;93:198-206</a>, <a href=\"https://pubmed.ncbi.nlm.nih.gov/26014209/\" target=\"_blank\">Jia et al. Psychooncology. 2015;24:1754-60</a>). Members considered the impact on family and wh\u0101nau is due to the need to support the patient with AML through this long and difficult illness. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that AML is the most common acute leukaemia diagnosed in New Zealand adults, with incidence estimated to be 6-9 per 100,000 in the population in 2016 (<a href=\"https://pubmed.ncbi.nlm.nih.gov/29860482/\" target=\"_blank\">Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2018;4:1553-68</a>). However, Members estimated that if AML secondary to prior haematological malignancy or previous treatment of malignant disease is excluded, the incidence of <i>de novo</i> AML in New Zealand is lower, closer to 3.5 per 100,000. The Subcommittee noted that AML incidence increases with age and that the median age at diagnosis is between 65 to 70 years. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that M\u0101ori have an increased risk of AML relative to New Zealand Caucasians (<a href=\"https://pubmed.ncbi.nlm.nih.gov/15929115/\" target=\"_blank\">Tracey et al. Am J Hematol. 2005;79:114-8</a>) and that M\u0101ori have reduced chances of finding suitable stem cell donors from international registries, leading to disproportionately less stem cell transplantation as part of therapy for AML.<span style=\"background-color: yellow; font-size: 7pt;\"> </span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that standard of care diagnostic investigation of patients with AML includes bone marrow sampling, molecular testing and immunophenotyping via flow cytometry; the latter of which would detect the cell surface antigen CD33 that is present for approximately 85\u201390% of patients with AML. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the health need and probability of survival for patients with AML is predominantly influenced by age and cytogenetic risk profile which can be categorised as favourable or intermediate (combined, these account for about 70% of <i>de novo</i> AML) or as adverse (~30% of cases). The Subcommittee noted that molecular testing identifies a range of genetic mutations in AML which occur in different patterns and combinations, contributing to a patient\u2019s cytogenetic risk: </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.6.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the FLT3 (FMS-like tyrosine kinase 3) mutation occurs in about one-third of patients with AML. The Subcommittee considered that patients with FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) experience more frequent and earlier disease relapse leading to poor survival.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.6.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that patients with acute promyelocytic leukaemia (APL) have a particular, mutation, that is associated with good outcomes from current treatment, therefore patients with APL were considered out of scope for the current funding applications. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.7.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that cytogenetic testing is routinely available across New Zealand and that results are generally available within 48 to 72 hours. The Subcommittee considered it important for cytogenetic results to be available before treatment commences to ensure therapy is optimal with regard to the patient\u2019s cytogenetics, however, unavoidable delays (e.g. due to public holidays) are known to lead to additional supportive care requirements while results are pending. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.8.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that approximately half to three-quarters of younger patients (generally defined as those aged less than 60 years) with AML are suitable for intensive induction and consolidation chemotherapy with anthracycline (e.g. daunorubicin) and cytarabine, both which are currently funded without restriction and remain the backbone of intensive treatment for AML. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.9.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that many New Zealand patients with AML have participated in UK-based clinical trials, most recently the AML-19 trial; a randomised, factorial design, open-label, phase III trial comparing several different treatment strategies (including gemtuzumab ozogamicin and midostaurin) in adults with <i>de novo</i> AML who are suitable for intensive chemotherapy. Members considered that early data from the AML-19 trial suggests an improvement in long-term survival in younger patients.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.10.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that azacitidine is not used to treat patients with AML who are deemed suitable for treatment with intensive chemotherapy. The Subcommittee considered that azacitidine is generally used in patients of older age, those who are frail, have low AML blast cell counts and have adverse cytogenetics. As a result, the Subcommittee considered that any widening of access to azacitidine for patients with AML would not affect the treatment paradigm for patients with AML who are suitable candidates for intensive chemotherapy.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.11.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that disease relapse, which is accompanied by a return of symptoms due to blast cell re-emergence, is of high unmet clinical need for patients with AML as there are limited subsequent treatment options and often very shortened survival post-relapse. The Subcommittee noted that younger patients with AML who receive intensive treatment have 5 year-survival rates of about 50% at 5 years and this rate has improved over past decades, predominantly driven by improved understanding of the disease, therapeutic approaches and molecular testing in clinical trials; however, patients over 60 have a lower rate of survival (about 25% at 5 years) and this has not improved substantially over past decades.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.12.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>Members noted that patients with AML with intermediate or adverse disease risk that is in remission after intensive chemotherapy treatment may be fit enough to undergo allogenic stem cell transplant, leading to better outcomes for such patients; however, older patients (e.g. patients over 60 years of age) may not be suitable candidates for transplant and therefore are unable to receive this additional benefit.</p><p style=\"text-align: justify;\"><br></p><h2>Gemtuzumab ozogamicin</h2><p style=\"text-align: justify;\"><span style=\"color: black;\">1.13.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that in February <a href=\"https://connect.pharmac.govt.nz/apptracker/s/application-public/a0R2P000000MazW\" target=\"_blank\">2015</a>, PHARMAC received a clinician application to fund gemtuzumab ozogamicin in New Zealand for favourable and intermediate-risk AML within the context of the UK Medical Research Council (UK MRC) cooperative group trial, AML-19. The Subcommittee noted that the AML-19 clinical trial was discussed by CaTSoP in <a href=\"https://www.pharmac.govt.nz/assets/ptac-cancer-treatments-subcommittee-minutes-2015-03.pdf\" target=\"_blank\">March 2015</a> and that the clinician application was reviewed by <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf\" target=\"_blank\" style=\"color: windowtext;\">PTAC in </a><a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf\" target=\"_blank\">May 2015</a>, who noted gemtuzumab ozogamicin was not commercially available and recommended it be declined due to insufficient evidence to support funding it on the Pharmaceutical Schedule; subsequently, an exemption to the Hospital Medicines List was granted, enabling gemtuzumab ozogamicin use within the AML-19 clinical trial, for a maximum of three years. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.14.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that gemtuzumab ozogamicin is a monoclonal antibody to CD33 linked to a cytotoxic agent that selectively targets CD33-positive AML blast cells and induces cell death while selectively minimising the impact on cells and tissues that do not express CD33. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.15.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that a regulatory application for gemtuzumab ozogamicin was submitted to Medsafe in May 2020, and at this review this application was considered to meet PHARMAC\u2019s criteria for consideration under the parallel assessment pathway which provides for consideration of cancer medicines at the same time as they are assessed by Medsafe. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.16.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that gemtuzumab ozogamicin is available as 5 mg powder concentrate for infusion in a single-use vial and the applicants state it would be administered at a dose of 3 mg per m<sup>2</sup>, capped at 5 mg per dose, in combination with standard intensive anthracycline and cytarabine chemotherapy. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.17.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the supplier requested funding for three doses during induction therapy and up to two doses for consolidation therapy (total of five doses), however, the clinician applicants\u2019 requested that gemtuzumab ozogamicin be funded for one or two doses for induction therapy only. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.18.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the supplier additionally defined the patient group being considered for treatment with gemtuzumab ozogamicin as those who have CD-33 positive disease, whereas the clinician applicants defined the target patient group as those with good, intermediate or unknown cytogenetic risk treated with curative intent.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.19.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the key clinical trial evidence for gemtuzumab ozogamicin comes from the randomised (1:1), phase III, open-label ALFA 0701 trial, which investigated standard induction (daunorubicin 60 mg/m<sup>2</sup> and cytarabine 200 mg/m<sup>2</sup>), consolidation therapy (daunorubicin 60 mg/m<sup>2</sup> cytarabine 1 g/m<sup>2</sup>) with or without gemtuzumab ozogamicin 3 mg per m<sup>2 </sup>on days 1, 4, and 7 of induction and day 1 of consolidation courses (total of 5 doses) in 280 patients aged 55 to 70 years with previously untreated de novo acute AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/22482940/\" target=\"_blank\">Castaigne et al. Lancet. 2012;379:1508-16</a>). </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.20.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the primary outcome of ALFA 0701 was event free .survival (EFS, defined as time from randomisation to relapse, death [any cause], or failure to achieve complete remission [CR] or complete remission with incomplete haematological recovery [CRp]) and that following a relapse event, patients could undergo salvage treatment. The Committee noted that 177 of 280 patients tolerated the treatment well enough to receive the entire regimen. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.21.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the ALFA 0701 trial results report an improvement in EFS (HR 0.58, 95% CI: 0.43-0.78; P=0.0003) and a lesser improvement in overall survival (OS) (HR for death 0.69, 95% CI: 0.49-0.98; P=0.0368). The Subcommittee considered that salvage treatment of patients post-relapse could have resulted in some of the reported OS benefit. The Subcommittee noted that the rates of death due to major toxicity were similar between the treatment groups. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.22.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that persistent grade 4 thrombocytopenia was reported in in 22 patients (16%) receiving gemtuzumab ozogamicin in the ALFA 0701 trial compared with 4 patients (3%) in the control group (P&lt;0.0001), longer treatment-induced neutropenia was reported in patients receiving gemtuzumab ozogamicin, and there were generally increased rates of grade 3 and 4 adverse events in patients receiving gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.23.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the ALFA 0701 trial final OS results, which reported a modest improvement in OS (although not statistically significant) with median OS 27.5 months (95% CI: 21.4-45.6) with gemtuzumab ozogamicin compared with 21.8 months (95% CI: 15.5-27.4) in the control group (HR 0.81, 95% CI: 0.60-1.09; 2-sided <i>P</i>=0.16) (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\">Lambert et al. Haematologica. 2019;104:113-9</a>). The Subcommittee noted that OS analysis in patient subsets indicated that younger patients and patients with favourable and intermediate cytogenetic risk receive a survival benefit (HR: 0.46, 95% CI: 0.31-0.68; <i>P</i>&lt;0.0001); however, the data indicated that patients with unfavourable cytogenetics (irrespective of mutation e.g. FLT3, NPM1 or other type) did not benefit from the addition of gemtuzumab ozogamicin (HR: 1.11, 95% CI: 0.63-1.95;P=0.72). Members noted that the trial population included more patients with intermediate cytogenetic risk than favourable cytogenetic risk (<a href=\"https://www.thelancet.com/action/showPdf?pii=S0140-6736%2812%2960485-1\" target=\"_blank\">Castaigne et al. Lancet. 2012;379:1508-16</a>). Members considered despite the limited trial data for patients with favourable cytogenetic risk it was likely that they also benefitted from treatment with gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.24.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the results of a meta-analysis of five randomised controlled trials, in which gemtuzumab ozogamicin was used at a dose of 3 mg per m<sup>2</sup> (single or multiple doses) or at 6 mg per m<sup>2</sup> as part of intensive induction therapy in a total of 3,325 adult patients with AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\">Hills et al. Lancet Oncol. 2014;15:986-96</a>). The Subcommittee noted that this meta-analysis included the open-label, randomised AML-15 trial in patients with AML (excluding APL) who were mostly less than 60 years of age (<a href=\"https://pubmed.ncbi.nlm.nih.gov/21172891/\" target=\"_blank\">Burnett et al. J Clin Oncol. 2011; 29:369-77</a>). </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.25.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the meta-analysis by Hills et al. reported that the rate of remission was unchanged, the risk of relapse was reduced (odds ratio [OR]: 0.81, 95% CI: 0.73 \u2013 0.90, <i>P</i>=0.0001) and OS at five years was increased (OR: 0.90, 95% CI: 0.82 \u2013 0.98, <i>P</i>=0.01) with gemtuzumab ozogamicin in intensively treated patients. The Subcommittee noted that after treatment with gemtuzumab ozogamicin, 20.7% (OR: 0.47) more patients with favourable cytogenetic risk and 5.7% (OR: 0.84) more patients with intermediate risk respectively remained alive after 6 years than those who did not receive gemtuzumab ozogamicin, however, those with adverse risk cytogenetics did not benefit from gemtuzumab ozogamicin. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.26.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee also noted the applicant-submitted data for gemtuzumab ozogamicin from the AAML0531 trial in patients aged 0 to 29 years with newly diagnosed AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25092781\" target=\"_blank\">Gamis et al. J Clin Oncol. 2014;32:3021-32</a>).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.27.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that approximately 88 patients with AML would be fit for intensive chemotherapy each year in New Zealand, of which approximately three-quarters (66 patients) would have favourable, intermediate or undetermined cytogenetics and would therefore be potentially eligible for gemtuzumab ozogamicin. The Subcommittee considered this estimate was sufficiently close to that of the applicants (45 patients per year).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.28.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that gemtuzumab ozogamicin would provide a treatment benefit for the group of patients with AML with favourable, intermediate or undetermined cytogenetic risk and therefore the funded benefit would reach many people with AML. The Subcommittee considered that the use of gemtuzumab ozogamicin, if funded, would not change usage of other funded medicines used to treat AML, however there may be additional platelet transfusion requirements as more patients would achieve complete remission with incomplete platelet recovery after treatment with gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.29.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that the Special Authority criteria for gemtuzumab ozogamicin should include favourable and intermediate, but not unknown, cytogenetic risk; treatment with gemtuzumab ozogamicin should be commenced after cytogenetic testing results are made available.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.30.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that, based on the mature published evidence and unpublished emerging evidence (i.e. AML 19 trial data) for gemtuzumab ozogamicin at this time, a single dose of gemtuzumab ozogamicin would likely provide sufficient benefit in terms of relapse rate and survival compared with two or five doses for patients with favourable, intermediate or undetermined risk AML, noting the risk of liver toxicity or thrombocytopenia that may develop as a result of additional doses during intensive treatment, and which may preclude subsequent transplant, as well as the incremental cost of additional doses. The Subcommittee considered that it was reasonable to specify a maximum of one dose of gemtuzumab ozogamicin in the Special Authority criteria based on this assessment.\u00a0</p><p style=\"text-align: justify;\"><br></p>",
          "change": null
        },
        "Published_Application": {
          "s": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1. </span>The Subcommittee considered the following applications for gemtuzumab ozogamicin:</p><p style=\"text-align: justify;\">1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>Clinician applications for gemtuzumab ozogamicin for the treatment of patients with AML, submitted on behalf of the New Zealand Branch of the Haematology Society of Australia and New Zealand and the National New Zealand Haematology Trials Group; and</p><p style=\"text-align: justify;\">1.1.2. A supporting supplier application from Pfizer for gemtuzumab ozogamicin (Mylotarg) was received in May 2020, for combination therapy with standard anthracycline and cytarabine for patients aged 15 years and above with previously untreated, de novo acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2. </span>The Subcommittee noted that, the clinician applications for gemtuzumab ozogamicin and midostaurin refer to patients with acute myeloid leukaemia (AML) and in addition, those who may participate in the UK Medical Research Council (MRC) AML-19 clinical trial. The Subcommittee considered the above applications for gemtuzumab ozogamicin and midostaurin for listing on the Pharmaceutical Schedule for the treatment of AML, irrespective of clinical trial participation.</p><p style=\"text-align: justify;\"><br></p>",
          "fs": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1. </span>The Subcommittee considered the following applications for gemtuzumab ozogamicin:</p><p style=\"text-align: justify;\">1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>Clinician applications for gemtuzumab ozogamicin for the treatment of patients with AML, submitted on behalf of the New Zealand Branch of the Haematology Society of Australia and New Zealand and the National New Zealand Haematology Trials Group; and</p><p style=\"text-align: justify;\">1.1.2. A supporting supplier application from Pfizer for gemtuzumab ozogamicin (Mylotarg) was received in May 2020, for combination therapy with standard anthracycline and cytarabine for patients aged 15 years and above with previously untreated, de novo acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2. </span>The Subcommittee noted that, the clinician applications for gemtuzumab ozogamicin and midostaurin refer to patients with acute myeloid leukaemia (AML) and in addition, those who may participate in the UK Medical Research Council (MRC) AML-19 clinical trial. The Subcommittee considered the above applications for gemtuzumab ozogamicin and midostaurin for listing on the Pharmaceutical Schedule for the treatment of AML, irrespective of clinical trial participation.</p><p style=\"text-align: justify;\"><br></p>",
          "change": null
        },
        "PTAC_Comments": {
          "s": "<p>At the August 2020 of PTAC The Committee </p><p><br></p><p>The Committee noted that M\u0101ori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP\u2019s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML. </p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\" style=\"color: windowtext;\">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"color: windowtext;\">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP\u2019s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28644114/\" target=\"_blank\" style=\"color: windowtext;\">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\u00a0</p>",
          "fs": "<p>At the August 2020 of PTAC The Committee </p><p><br></p><p>The Committee noted that M\u0101ori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP\u2019s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML. </p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\" style=\"color: windowtext;\">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"color: windowtext;\">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP\u2019s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28644114/\" target=\"_blank\" style=\"color: windowtext;\">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\u00a0</p>",
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2020",
          "fs": "Sep 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.",
          "fs": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7kUAA"
          },
          "Id": "a0P2P0000078q7kUAA",
          "Event_Date__c": "2020-09-29",
          "Event_Description__c": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Formatted_Date__c": "Sep 2020",
          "Published_Recommendation__c": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that gemtuzumab ozogamicin (one dose only, with intensive chemotherapy) be funded for the treatment of <i>de novo</i> acute myeloid leukaemia with a high priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Initial application \u2014 only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has not received prior chemotherapy for this condition; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has de novo CD33-positive acute myeloid leukaemia; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient does not have acute promyelocytic leukaemia; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">4</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC); and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">5</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient is being treated with curative intent; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">6</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient\u2019s disease risk has been assessed by cytogenetic testing to be good or intermediate; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient must be considered eligible for standard intensive remission induction chemotherapy with daunorubicin and cytarabine; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">8</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Gemtuzumab ozogamicin to be funded for one dose only.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Notes: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (e.g. myelodysplasia or myeloproliferative disorder).</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>In making this recommendation, the Subcommittee noted that the supplier of gemtuzumab ozogamicin had requested funding for five doses. However, the Subcommittee considered that the incremental benefit of five doses, compared with a single dose, was not sufficient to warrant the additional four doses. The Subcommittee considered that there was likely a small additional benefit in relapse rate and survival from five doses compared with that provided by one dose of gemtuzumab ozogamicin, and that the potential for treatment-related toxicity may also preclude subsequent transplant.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(62, 62, 60);\">The Subcommittee also considered that, if PHARMAC was only able to fund one of these medicines (i.e gemtuzumab ozogamicin or midostaurin) for the treatment of patients with favourable, intermediate or undetermined risk AML, the greater clinical benefit could be obtained through first funding gemtuzumab ozogamicin, as this would result in benefits for a wider population rather than a defined subset of the population.</span></p><p style=\"text-align: justify;\"><br></p>",
          "Published_Application__c": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1. </span>The Subcommittee considered the following applications for gemtuzumab ozogamicin:</p><p style=\"text-align: justify;\">1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>Clinician applications for gemtuzumab ozogamicin for the treatment of patients with AML, submitted on behalf of the New Zealand Branch of the Haematology Society of Australia and New Zealand and the National New Zealand Haematology Trials Group; and</p><p style=\"text-align: justify;\">1.1.2. A supporting supplier application from Pfizer for gemtuzumab ozogamicin (Mylotarg) was received in May 2020, for combination therapy with standard anthracycline and cytarabine for patients aged 15 years and above with previously untreated, de novo acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2. </span>The Subcommittee noted that, the clinician applications for gemtuzumab ozogamicin and midostaurin refer to patients with acute myeloid leukaemia (AML) and in addition, those who may participate in the UK Medical Research Council (MRC) AML-19 clinical trial. The Subcommittee considered the above applications for gemtuzumab ozogamicin and midostaurin for listing on the Pharmaceutical Schedule for the treatment of AML, irrespective of clinical trial participation.</p><p style=\"text-align: justify;\"><br></p>",
          "Published_Discussion__c": "<p style=\"text-align: justify;\"><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0</span>The Subcommittee noted that acute myeloid leukaemia (AML) is a haematopoietic neoplasm involving clonal proliferation of myeloid precursor cells, leading to increased production of immature malignant cells and a reduction in mature myeloid cells. The Subcommittee noted that AML is a highly symptomatic, rapidly progressing disease that results in a variety of systemic consequences (e.g. anaemia, bleeding, and an increased risk of infection) due to bone marrow failure or the presence of AML blasts in the bone marrow, peripheral blood or other organs, with poor overall survival. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that patients with AML spend a substantial amount of time in hospital for disease management, treatment administration, supportive care and investigations; this inpatient duration may be weeks or months for patients who receive intensive chemotherapy. The Subcommittee noted evidence where the caregivers of patients with AML, in addition to patients themselves, experienced post-traumatic stress (<a href=\"https://pubmed.ncbi.nlm.nih.gov/24673368/\" target=\"_blank\">Leunis et al. Eur J Haematol. 2014;93:198-206</a>, <a href=\"https://pubmed.ncbi.nlm.nih.gov/26014209/\" target=\"_blank\">Jia et al. Psychooncology. 2015;24:1754-60</a>). Members considered the impact on family and wh\u0101nau is due to the need to support the patient with AML through this long and difficult illness. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that AML is the most common acute leukaemia diagnosed in New Zealand adults, with incidence estimated to be 6-9 per 100,000 in the population in 2016 (<a href=\"https://pubmed.ncbi.nlm.nih.gov/29860482/\" target=\"_blank\">Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2018;4:1553-68</a>). However, Members estimated that if AML secondary to prior haematological malignancy or previous treatment of malignant disease is excluded, the incidence of <i>de novo</i> AML in New Zealand is lower, closer to 3.5 per 100,000. The Subcommittee noted that AML incidence increases with age and that the median age at diagnosis is between 65 to 70 years. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that M\u0101ori have an increased risk of AML relative to New Zealand Caucasians (<a href=\"https://pubmed.ncbi.nlm.nih.gov/15929115/\" target=\"_blank\">Tracey et al. Am J Hematol. 2005;79:114-8</a>) and that M\u0101ori have reduced chances of finding suitable stem cell donors from international registries, leading to disproportionately less stem cell transplantation as part of therapy for AML.<span style=\"background-color: yellow; font-size: 7pt;\"> </span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that standard of care diagnostic investigation of patients with AML includes bone marrow sampling, molecular testing and immunophenotyping via flow cytometry; the latter of which would detect the cell surface antigen CD33 that is present for approximately 85\u201390% of patients with AML. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the health need and probability of survival for patients with AML is predominantly influenced by age and cytogenetic risk profile which can be categorised as favourable or intermediate (combined, these account for about 70% of <i>de novo</i> AML) or as adverse (~30% of cases). The Subcommittee noted that molecular testing identifies a range of genetic mutations in AML which occur in different patterns and combinations, contributing to a patient\u2019s cytogenetic risk: </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.6.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the FLT3 (FMS-like tyrosine kinase 3) mutation occurs in about one-third of patients with AML. The Subcommittee considered that patients with FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) experience more frequent and earlier disease relapse leading to poor survival.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\">1.6.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that patients with acute promyelocytic leukaemia (APL) have a particular, mutation, that is associated with good outcomes from current treatment, therefore patients with APL were considered out of scope for the current funding applications. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.7.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that cytogenetic testing is routinely available across New Zealand and that results are generally available within 48 to 72 hours. The Subcommittee considered it important for cytogenetic results to be available before treatment commences to ensure therapy is optimal with regard to the patient\u2019s cytogenetics, however, unavoidable delays (e.g. due to public holidays) are known to lead to additional supportive care requirements while results are pending. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.8.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that approximately half to three-quarters of younger patients (generally defined as those aged less than 60 years) with AML are suitable for intensive induction and consolidation chemotherapy with anthracycline (e.g. daunorubicin) and cytarabine, both which are currently funded without restriction and remain the backbone of intensive treatment for AML. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.9.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that many New Zealand patients with AML have participated in UK-based clinical trials, most recently the AML-19 trial; a randomised, factorial design, open-label, phase III trial comparing several different treatment strategies (including gemtuzumab ozogamicin and midostaurin) in adults with <i>de novo</i> AML who are suitable for intensive chemotherapy. Members considered that early data from the AML-19 trial suggests an improvement in long-term survival in younger patients.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.10.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that azacitidine is not used to treat patients with AML who are deemed suitable for treatment with intensive chemotherapy. The Subcommittee considered that azacitidine is generally used in patients of older age, those who are frail, have low AML blast cell counts and have adverse cytogenetics. As a result, the Subcommittee considered that any widening of access to azacitidine for patients with AML would not affect the treatment paradigm for patients with AML who are suitable candidates for intensive chemotherapy.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.11.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that disease relapse, which is accompanied by a return of symptoms due to blast cell re-emergence, is of high unmet clinical need for patients with AML as there are limited subsequent treatment options and often very shortened survival post-relapse. The Subcommittee noted that younger patients with AML who receive intensive treatment have 5 year-survival rates of about 50% at 5 years and this rate has improved over past decades, predominantly driven by improved understanding of the disease, therapeutic approaches and molecular testing in clinical trials; however, patients over 60 have a lower rate of survival (about 25% at 5 years) and this has not improved substantially over past decades.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.12.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>Members noted that patients with AML with intermediate or adverse disease risk that is in remission after intensive chemotherapy treatment may be fit enough to undergo allogenic stem cell transplant, leading to better outcomes for such patients; however, older patients (e.g. patients over 60 years of age) may not be suitable candidates for transplant and therefore are unable to receive this additional benefit.</p><p style=\"text-align: justify;\"><br></p><h2>Gemtuzumab ozogamicin</h2><p style=\"text-align: justify;\"><span style=\"color: black;\">1.13.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that in February <a href=\"https://connect.pharmac.govt.nz/apptracker/s/application-public/a0R2P000000MazW\" target=\"_blank\">2015</a>, PHARMAC received a clinician application to fund gemtuzumab ozogamicin in New Zealand for favourable and intermediate-risk AML within the context of the UK Medical Research Council (UK MRC) cooperative group trial, AML-19. The Subcommittee noted that the AML-19 clinical trial was discussed by CaTSoP in <a href=\"https://www.pharmac.govt.nz/assets/ptac-cancer-treatments-subcommittee-minutes-2015-03.pdf\" target=\"_blank\">March 2015</a> and that the clinician application was reviewed by <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf\" target=\"_blank\" style=\"color: windowtext;\">PTAC in </a><a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf\" target=\"_blank\">May 2015</a>, who noted gemtuzumab ozogamicin was not commercially available and recommended it be declined due to insufficient evidence to support funding it on the Pharmaceutical Schedule; subsequently, an exemption to the Hospital Medicines List was granted, enabling gemtuzumab ozogamicin use within the AML-19 clinical trial, for a maximum of three years. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.14.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that gemtuzumab ozogamicin is a monoclonal antibody to CD33 linked to a cytotoxic agent that selectively targets CD33-positive AML blast cells and induces cell death while selectively minimising the impact on cells and tissues that do not express CD33. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.15.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that a regulatory application for gemtuzumab ozogamicin was submitted to Medsafe in May 2020, and at this review this application was considered to meet PHARMAC\u2019s criteria for consideration under the parallel assessment pathway which provides for consideration of cancer medicines at the same time as they are assessed by Medsafe. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.16.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that gemtuzumab ozogamicin is available as 5 mg powder concentrate for infusion in a single-use vial and the applicants state it would be administered at a dose of 3 mg per m<sup>2</sup>, capped at 5 mg per dose, in combination with standard intensive anthracycline and cytarabine chemotherapy. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.17.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the supplier requested funding for three doses during induction therapy and up to two doses for consolidation therapy (total of five doses), however, the clinician applicants\u2019 requested that gemtuzumab ozogamicin be funded for one or two doses for induction therapy only. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.18.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the supplier additionally defined the patient group being considered for treatment with gemtuzumab ozogamicin as those who have CD-33 positive disease, whereas the clinician applicants defined the target patient group as those with good, intermediate or unknown cytogenetic risk treated with curative intent.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.19.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the key clinical trial evidence for gemtuzumab ozogamicin comes from the randomised (1:1), phase III, open-label ALFA 0701 trial, which investigated standard induction (daunorubicin 60 mg/m<sup>2</sup> and cytarabine 200 mg/m<sup>2</sup>), consolidation therapy (daunorubicin 60 mg/m<sup>2</sup> cytarabine 1 g/m<sup>2</sup>) with or without gemtuzumab ozogamicin 3 mg per m<sup>2 </sup>on days 1, 4, and 7 of induction and day 1 of consolidation courses (total of 5 doses) in 280 patients aged 55 to 70 years with previously untreated de novo acute AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/22482940/\" target=\"_blank\">Castaigne et al. Lancet. 2012;379:1508-16</a>). </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.20.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the primary outcome of ALFA 0701 was event free .survival (EFS, defined as time from randomisation to relapse, death [any cause], or failure to achieve complete remission [CR] or complete remission with incomplete haematological recovery [CRp]) and that following a relapse event, patients could undergo salvage treatment. The Committee noted that 177 of 280 patients tolerated the treatment well enough to receive the entire regimen. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.21.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the ALFA 0701 trial results report an improvement in EFS (HR 0.58, 95% CI: 0.43-0.78; P=0.0003) and a lesser improvement in overall survival (OS) (HR for death 0.69, 95% CI: 0.49-0.98; P=0.0368). The Subcommittee considered that salvage treatment of patients post-relapse could have resulted in some of the reported OS benefit. The Subcommittee noted that the rates of death due to major toxicity were similar between the treatment groups. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.22.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that persistent grade 4 thrombocytopenia was reported in in 22 patients (16%) receiving gemtuzumab ozogamicin in the ALFA 0701 trial compared with 4 patients (3%) in the control group (P&lt;0.0001), longer treatment-induced neutropenia was reported in patients receiving gemtuzumab ozogamicin, and there were generally increased rates of grade 3 and 4 adverse events in patients receiving gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.23.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the ALFA 0701 trial final OS results, which reported a modest improvement in OS (although not statistically significant) with median OS 27.5 months (95% CI: 21.4-45.6) with gemtuzumab ozogamicin compared with 21.8 months (95% CI: 15.5-27.4) in the control group (HR 0.81, 95% CI: 0.60-1.09; 2-sided <i>P</i>=0.16) (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\">Lambert et al. Haematologica. 2019;104:113-9</a>). The Subcommittee noted that OS analysis in patient subsets indicated that younger patients and patients with favourable and intermediate cytogenetic risk receive a survival benefit (HR: 0.46, 95% CI: 0.31-0.68; <i>P</i>&lt;0.0001); however, the data indicated that patients with unfavourable cytogenetics (irrespective of mutation e.g. FLT3, NPM1 or other type) did not benefit from the addition of gemtuzumab ozogamicin (HR: 1.11, 95% CI: 0.63-1.95;P=0.72). Members noted that the trial population included more patients with intermediate cytogenetic risk than favourable cytogenetic risk (<a href=\"https://www.thelancet.com/action/showPdf?pii=S0140-6736%2812%2960485-1\" target=\"_blank\">Castaigne et al. Lancet. 2012;379:1508-16</a>). Members considered despite the limited trial data for patients with favourable cytogenetic risk it was likely that they also benefitted from treatment with gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.24.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted the results of a meta-analysis of five randomised controlled trials, in which gemtuzumab ozogamicin was used at a dose of 3 mg per m<sup>2</sup> (single or multiple doses) or at 6 mg per m<sup>2</sup> as part of intensive induction therapy in a total of 3,325 adult patients with AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\">Hills et al. Lancet Oncol. 2014;15:986-96</a>). The Subcommittee noted that this meta-analysis included the open-label, randomised AML-15 trial in patients with AML (excluding APL) who were mostly less than 60 years of age (<a href=\"https://pubmed.ncbi.nlm.nih.gov/21172891/\" target=\"_blank\">Burnett et al. J Clin Oncol. 2011; 29:369-77</a>). </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.25.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee noted that the meta-analysis by Hills et al. reported that the rate of remission was unchanged, the risk of relapse was reduced (odds ratio [OR]: 0.81, 95% CI: 0.73 \u2013 0.90, <i>P</i>=0.0001) and OS at five years was increased (OR: 0.90, 95% CI: 0.82 \u2013 0.98, <i>P</i>=0.01) with gemtuzumab ozogamicin in intensively treated patients. The Subcommittee noted that after treatment with gemtuzumab ozogamicin, 20.7% (OR: 0.47) more patients with favourable cytogenetic risk and 5.7% (OR: 0.84) more patients with intermediate risk respectively remained alive after 6 years than those who did not receive gemtuzumab ozogamicin, however, those with adverse risk cytogenetics did not benefit from gemtuzumab ozogamicin. </p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.26.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee also noted the applicant-submitted data for gemtuzumab ozogamicin from the AAML0531 trial in patients aged 0 to 29 years with newly diagnosed AML (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25092781\" target=\"_blank\">Gamis et al. J Clin Oncol. 2014;32:3021-32</a>).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.27.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that approximately 88 patients with AML would be fit for intensive chemotherapy each year in New Zealand, of which approximately three-quarters (66 patients) would have favourable, intermediate or undetermined cytogenetics and would therefore be potentially eligible for gemtuzumab ozogamicin. The Subcommittee considered this estimate was sufficiently close to that of the applicants (45 patients per year).</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.28.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that gemtuzumab ozogamicin would provide a treatment benefit for the group of patients with AML with favourable, intermediate or undetermined cytogenetic risk and therefore the funded benefit would reach many people with AML. The Subcommittee considered that the use of gemtuzumab ozogamicin, if funded, would not change usage of other funded medicines used to treat AML, however there may be additional platelet transfusion requirements as more patients would achieve complete remission with incomplete platelet recovery after treatment with gemtuzumab ozogamicin.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.29.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that the Special Authority criteria for gemtuzumab ozogamicin should include favourable and intermediate, but not unknown, cytogenetic risk; treatment with gemtuzumab ozogamicin should be commenced after cytogenetic testing results are made available.</p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"color: black;\">1.30.</span><span style=\"color: black; font-size: 7pt;\">\u00a0</span>The Subcommittee considered that, based on the mature published evidence and unpublished emerging evidence (i.e. AML 19 trial data) for gemtuzumab ozogamicin at this time, a single dose of gemtuzumab ozogamicin would likely provide sufficient benefit in terms of relapse rate and survival compared with two or five doses for patients with favourable, intermediate or undetermined risk AML, noting the risk of liver toxicity or thrombocytopenia that may develop as a result of additional doses during intensive treatment, and which may preclude subsequent transplant, as well as the incremental cost of additional doses. The Subcommittee considered that it was reasonable to specify a maximum of one dose of gemtuzumab ozogamicin in the Special Authority criteria based on this assessment.\u00a0</p><p style=\"text-align: justify;\"><br></p>",
          "PTAC_Comments__c": "<p>At the August 2020 of PTAC The Committee </p><p><br></p><p>The Committee noted that M\u0101ori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP\u2019s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML. </p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\" style=\"color: windowtext;\">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"color: windowtext;\">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP\u2019s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28644114/\" target=\"_blank\" style=\"color: windowtext;\">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\u00a0</p>",
          "Status_History__c": "a132P000000CDBxQAO"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that at its <a href=\"https://pharmac.govt.nz/assets/2020-07-03-Catsop-Record-Web-version-Final-ready-to-upload.pdf\" target=\"_blank\" style=\"font-size: 12pt;\"><b>July 2020</b></a> meeting it had recommended that gemtuzumab ozogamicin (one dose only, with intensive chemotherapy) be funded for the treatment of de novo acute myeloid leukaemia with a high priority within the context of treatment of malignancy, subject to Special Authority criteria.</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the applicant\u2019s correspondence and request to remove the capped dosing at 5 mg for all patients if one dose were to be funded. The Subcommittee considered that this would require a large proportion of the population to need greater than one vial of gemtuzumab-ozogamicin for patients with acute myeloid leukemia (AML).</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee reviewed the dosing regimen for gemtuzumab-ozogamicin in the AML15 and AML16 trials (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Hills et al. Lancet Oncol. 2014;15:986-96</b></a>;<b> </b><a href=\"https://pubmed.ncbi.nlm.nih.gov/21172891/\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Burnett et al. J Clin Oncol. 2011;29:369-77</b></a>;<b> </b><a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.2964?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Burnett et al. J Clin Oncol. 2012;30:3924\u201331</b></a>), and unpublished emerging evidence (AML 19 and AML 18 trial data]), and considered that it was appropriate for the recommendation for dosing to reflect this evidence. Therefore, the Subcommittee considered that it was appropriate to change the recommended dosing regimen to 3 mg per m<span style=\"font-size: 9.75px;\">2</span>.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that most patients would require more than one vial, and considered that there would not be the ability to undertake vial sharing, given the low frequency of administration of gemtuzumab-ozogamicin. The Subcommittee considered that the increased requirement for vials would incur a significant additional cost, although noted that rounding weight-based dosing volumes to the nearest 10% is very common for similar products, which may reduce some of that large cost increment to a small extent.</p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee maintained its high priority recommendation for gemtuzumab ozogamicin in this setting, even with the removal of the capped dosing regimen.</p>",
          "fs": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that at its <a href=\"https://pharmac.govt.nz/assets/2020-07-03-Catsop-Record-Web-version-Final-ready-to-upload.pdf\" target=\"_blank\" style=\"font-size: 12pt;\"><b>July 2020</b></a> meeting it had recommended that gemtuzumab ozogamicin (one dose only, with intensive chemotherapy) be funded for the treatment of de novo acute myeloid leukaemia with a high priority within the context of treatment of malignancy, subject to Special Authority criteria.</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the applicant\u2019s correspondence and request to remove the capped dosing at 5 mg for all patients if one dose were to be funded. The Subcommittee considered that this would require a large proportion of the population to need greater than one vial of gemtuzumab-ozogamicin for patients with acute myeloid leukemia (AML).</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee reviewed the dosing regimen for gemtuzumab-ozogamicin in the AML15 and AML16 trials (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Hills et al. Lancet Oncol. 2014;15:986-96</b></a>;<b> </b><a href=\"https://pubmed.ncbi.nlm.nih.gov/21172891/\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Burnett et al. J Clin Oncol. 2011;29:369-77</b></a>;<b> </b><a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.2964?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Burnett et al. J Clin Oncol. 2012;30:3924\u201331</b></a>), and unpublished emerging evidence (AML 19 and AML 18 trial data]), and considered that it was appropriate for the recommendation for dosing to reflect this evidence. Therefore, the Subcommittee considered that it was appropriate to change the recommended dosing regimen to 3 mg per m<span style=\"font-size: 9.75px;\">2</span>.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that most patients would require more than one vial, and considered that there would not be the ability to undertake vial sharing, given the low frequency of administration of gemtuzumab-ozogamicin. The Subcommittee considered that the increased requirement for vials would incur a significant additional cost, although noted that rounding weight-based dosing volumes to the nearest 10% is very common for similar products, which may reduce some of that large cost increment to a small extent.</p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee maintained its high priority recommendation for gemtuzumab ozogamicin in this setting, even with the removal of the capped dosing regimen.</p>",
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": "<p>The Committee noted that M\u0101ori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP\u2019s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML. </p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\" style=\"color: windowtext;\">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"color: windowtext;\">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP\u2019s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML.</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28644114/\" target=\"_blank\" style=\"color: windowtext;\">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\u00a0</p>",
          "fs": "<p>The Committee noted that M\u0101ori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP\u2019s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML. </p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\" style=\"color: windowtext;\">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"color: windowtext;\">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP\u2019s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML.</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28644114/\" target=\"_blank\" style=\"color: windowtext;\">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\u00a0</p>",
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2020",
          "fs": "Oct 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.",
          "fs": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7lUAA"
          },
          "Id": "a0P2P0000078q7lUAA",
          "Event_Date__c": "2020-10-16",
          "Event_Description__c": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Formatted_Date__c": "Oct 2020",
          "Published_Discussion__c": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that at its <a href=\"https://pharmac.govt.nz/assets/2020-07-03-Catsop-Record-Web-version-Final-ready-to-upload.pdf\" target=\"_blank\" style=\"font-size: 12pt;\"><b>July 2020</b></a> meeting it had recommended that gemtuzumab ozogamicin (one dose only, with intensive chemotherapy) be funded for the treatment of de novo acute myeloid leukaemia with a high priority within the context of treatment of malignancy, subject to Special Authority criteria.</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the applicant\u2019s correspondence and request to remove the capped dosing at 5 mg for all patients if one dose were to be funded. The Subcommittee considered that this would require a large proportion of the population to need greater than one vial of gemtuzumab-ozogamicin for patients with acute myeloid leukemia (AML).</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee reviewed the dosing regimen for gemtuzumab-ozogamicin in the AML15 and AML16 trials (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Hills et al. Lancet Oncol. 2014;15:986-96</b></a>;<b> </b><a href=\"https://pubmed.ncbi.nlm.nih.gov/21172891/\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Burnett et al. J Clin Oncol. 2011;29:369-77</b></a>;<b> </b><a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.2964?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\" style=\"font-size: 12pt;\"><b>Burnett et al. J Clin Oncol. 2012;30:3924\u201331</b></a>), and unpublished emerging evidence (AML 19 and AML 18 trial data]), and considered that it was appropriate for the recommendation for dosing to reflect this evidence. Therefore, the Subcommittee considered that it was appropriate to change the recommended dosing regimen to 3 mg per m<span style=\"font-size: 9.75px;\">2</span>.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that most patients would require more than one vial, and considered that there would not be the ability to undertake vial sharing, given the low frequency of administration of gemtuzumab-ozogamicin. The Subcommittee considered that the increased requirement for vials would incur a significant additional cost, although noted that rounding weight-based dosing volumes to the nearest 10% is very common for similar products, which may reduce some of that large cost increment to a small extent.</p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee maintained its high priority recommendation for gemtuzumab ozogamicin in this setting, even with the removal of the capped dosing regimen.</p>",
          "PTAC_Comments__c": "<p>The Committee noted that M\u0101ori have an increased prevalence and risk of AML compared to New Zealand Caucasians.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund gemtuzumab-ozogamicin with a high priority and acknowledged CaTSoP\u2019s discussion of gemtuzumab-ozogamicin for the treatment of patients with favourable and intermediate cytogenetic risk AML. </p><p><br></p><p>The Committee noted the results of the ALFA-0701 trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30076173\" target=\"_blank\" style=\"color: windowtext;\">Lambert et al. Haematologica. 2019;104:113-9</a>) and the Hills et al. meta analysis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25008258/\" target=\"_blank\" style=\"color: windowtext;\">Hills et al. Lancet Oncol. 2014;15:986-96</a>) which indicated an event free survival improvement for gemtuzumab-ozogamicin compared with standard chemotherapy for the treatment of patients with intermediate or favourable cytogenetic risk AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for gemtuzumab-ozogamicin compared with standard chemotherapy in this population.</p><p><br></p><p>The Committee noted the Subcommittee\u2019s recommendation to fund midostaurin with a high priority and acknowledged CaTSoP\u2019s discussion of midostaurin for the treatment of patients with FLT3 mutation positive AML.</p><p><br></p><p>The Committee noted the results of the RATIFY trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28644114/\" target=\"_blank\" style=\"color: windowtext;\">Stone et al. N Engl J Med. 2017;377:454-64</a>) which indicated an event free survival improvement for midostaurin compared with standard chemotherapy for the treatment of patients with FLT3 mutation positive AML. The Committee considered there to be uncertainty regarding the overall survival and health related quality of life benefit for midostaurin compared to the standard chemotherapy for the treatment of FLT3 mutation positive AML.</p><p><br></p><p>The Committee considered that based on the available evidence that there was a greater survival benefit for midostaurin than that of gemtuzumab-ozogamicin. However, the Committee noted the higher relative priority consideration by CaTSoP for gemtuzumab-ozogamicin compared to midostaurin on the basis that gemtuzumab ozogamicin would result in benefits for a wider population of patients with AML.\u00a0</p>",
          "Status_History__c": "a132P000000CdHKQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jan 2021",
          "fs": "Jan 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7oUAA"
          },
          "Id": "a0P2P0000078q7oUAA",
          "Event_Date__c": "2021-01-10",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Jan 2021",
          "Status_History__c": "a132P000000EDcpQAG"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee reviewed correspondence from Pfizer that was received in December 2020 in relation to PTAC\u2019s review of CaTSoP\u2019s recommendation regarding its application for the funding of gemtuzumab-ozogamicin for the treatment of de novo acute myeloid leukaemia (AML).</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee clarified that it did not decline to provide a recommendation, but noted CaTSoP\u2019s recommendation for funding, and highlighted the uncertainties that related to the benefit that would occur with gemtuzumab-ozogamicin in this patient population.</p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the overall survival benefit was difficult to assess in this population, however considered that in fact there was a survival benefit from gemtuzumab-ozogamicin treatment, as discussed in the European Medicines Agency review of gemtuzumab-ozogamicin for the treatment of AML (<a href=\"https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0025\" target=\"_blank\">Ali, S. et al. The Oncol. 2019;24:e171-e179</a>). The Committee noted the differences in dose between that recommended by CaTSoP and that referenced by the supplier. The Committee however considered that CaTSoP was best placed to provide advice regarding the appropriate dosing for gemtuzumab-ozogamicin in this clinical group.</p>",
          "fs": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee reviewed correspondence from Pfizer that was received in December 2020 in relation to PTAC\u2019s review of CaTSoP\u2019s recommendation regarding its application for the funding of gemtuzumab-ozogamicin for the treatment of de novo acute myeloid leukaemia (AML).</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee clarified that it did not decline to provide a recommendation, but noted CaTSoP\u2019s recommendation for funding, and highlighted the uncertainties that related to the benefit that would occur with gemtuzumab-ozogamicin in this patient population.</p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the overall survival benefit was difficult to assess in this population, however considered that in fact there was a survival benefit from gemtuzumab-ozogamicin treatment, as discussed in the European Medicines Agency review of gemtuzumab-ozogamicin for the treatment of AML (<a href=\"https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0025\" target=\"_blank\">Ali, S. et al. The Oncol. 2019;24:e171-e179</a>). The Committee noted the differences in dose between that recommended by CaTSoP and that referenced by the supplier. The Committee however considered that CaTSoP was best placed to provide advice regarding the appropriate dosing for gemtuzumab-ozogamicin in this clinical group.</p>",
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "No Formal Recommendation",
          "fs": "No Formal Recommendation",
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf\" target=\"_blank\">Meeting record</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf\" target=\"_blank\">Meeting record</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2021",
          "fs": "May 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7pUAA"
          },
          "Id": "a0P2P0000078q7pUAA",
          "Event_Date__c": "2021-05-12",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf\" target=\"_blank\">Meeting record</a></p>",
          "Outcome__c": "No Formal Recommendation",
          "Formatted_Date__c": "May 2021",
          "Published_Discussion__c": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee reviewed correspondence from Pfizer that was received in December 2020 in relation to PTAC\u2019s review of CaTSoP\u2019s recommendation regarding its application for the funding of gemtuzumab-ozogamicin for the treatment of de novo acute myeloid leukaemia (AML).</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee clarified that it did not decline to provide a recommendation, but noted CaTSoP\u2019s recommendation for funding, and highlighted the uncertainties that related to the benefit that would occur with gemtuzumab-ozogamicin in this patient population.</p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the overall survival benefit was difficult to assess in this population, however considered that in fact there was a survival benefit from gemtuzumab-ozogamicin treatment, as discussed in the European Medicines Agency review of gemtuzumab-ozogamicin for the treatment of AML (<a href=\"https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0025\" target=\"_blank\">Ali, S. et al. The Oncol. 2019;24:e171-e179</a>). The Committee noted the differences in dose between that recommended by CaTSoP and that referenced by the supplier. The Committee however considered that CaTSoP was best placed to provide advice regarding the appropriate dosing for gemtuzumab-ozogamicin in this clinical group.</p>",
          "Status_History__c": "a132P000000EDdAQAW"
        },
        "change": null
      }
    ],
    "dateString": "Jun 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2020",
          "fs": "Nov 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7mUAA"
          },
          "Id": "a0P2P0000078q7mUAA",
          "Event_Date__c": "2020-11-24",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Nov 2020",
          "Status_History__c": "a132P000000CNQyQAO"
        },
        "change": null
      }
    ],
    "dateString": "Nov 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2020",
          "fs": "Dec 2020",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7nUAA"
          },
          "Id": "a0P2P0000078q7nUAA",
          "Event_Date__c": "2020-12-16",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Dec 2020",
          "Status_History__c": "a132P000000CSGtQAO"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2021",
          "fs": "Jun 2021",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7qUAA"
          },
          "Id": "a0P2P0000078q7qUAA",
          "Event_Date__c": "2021-06-25",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Jun 2021",
          "Status_History__c": "a132P000000CxMYQA0"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-fund-treatments-for-people-with-breast-and-blood-cancers/\" target=\"_blank\">Consultation for breast and blood cancer</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-fund-treatments-for-people-with-breast-and-blood-cancers/\" target=\"_blank\">Consultation for breast and blood cancer</a></p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2022",
          "fs": "May 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7rUAA"
          },
          "Id": "a0P2P0000078q7rUAA",
          "Event_Date__c": "2022-05-19",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Summary__c": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-fund-treatments-for-people-with-breast-and-blood-cancers/\" target=\"_blank\">Consultation for breast and blood cancer</a></p>",
          "Formatted_Date__c": "May 2022",
          "Status_History__c": "a132P000000DlvxQAC"
        },
        "change": null
      }
    ],
    "dateString": "May 2022",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2022",
          "fs": "Jun 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7sUAA"
          },
          "Id": "a0P2P0000078q7sUAA",
          "Event_Date__c": "2022-06-14",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Formatted_Date__c": "Jun 2022",
          "Status_History__c": "a132P000000DpXXQA0"
        },
        "change": null
      }
    ],
    "dateString": "Jun 2022",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-06-10-decision-to-fund-treatments-for-people-with-breast-and-blood-cancers/",
          "fs": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-06-10-decision-to-fund-treatments-for-people-with-breast-and-blood-cancers/",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2022",
          "fs": "Jun 2022",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been approved.",
          "fs": "The funding application has been approved.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078q7tUAA"
          },
          "Id": "a0P2P0000078q7tUAA",
          "Event_Date__c": "2022-06-14",
          "Event_Description__c": "The funding application has been approved.",
          "Stage__c": "Decision",
          "Summary__c": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-06-10-decision-to-fund-treatments-for-people-with-breast-and-blood-cancers/",
          "Formatted_Date__c": "Jun 2022",
          "Status_History__c": "a132P000000DpXcQAK"
        },
        "change": null
      }
    ],
    "dateString": "Jun 2022",
    "collapsed": false,
    "checked": true
  }
]